- #164: Artificial Intelligence in health care with a focus on hospitals: Methodological considerations for Health Technology Assessment
- #163: Threshold values in health economic evaluations and decision-making
- #162: Oncological Breast Cancer Care in Selected European Countries- Cross-sectoral cancer care models
- #161: ASSESS-DHT: Telehealth in Diabetes – EU mapping and systematic evaluation of organisational aspects
- #160: Strategies to reduce weight stigmatisation of people with overweight or obesity in the healthcare sector
- #159: Mental health screening of adults in primary care
- #158: The Role of Public Contributions to the Development of Health Innovations
- #124/1. Update 2024: Point of Care Tests (POCT): D-Dimer und Troponin
- #107/ 1. Update. 2024: Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer
- DSD 141: Thermoablation for benign thyroid nodules
- DSD 140: Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia
- DSD 139: Caval valve implantation for severe tricuspid regurgitation
- Update / DSD 45/2. Update 2024: Renal denervation (RDN) in patients with treatment resistant hypertension
- Update / DSD 24/3. Update 2014: Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD)
- HTA-Information Service Review No. 015
Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets - HTA-Information Service Review No. 014
Skin cancer prevention: Guideline recommendations for primary and secondary prevention - HTA-Information Service Review No. 013
CAR-based immunotherapy with a focus on CAR-NK cells - HTA-Information Service Review No. 012
Use of telepathology for intraoperative frozen section examination - HTA-Information Service Review No. 011
Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023 - HTA -Information Service Review No. 010
Biomarkers in Parkinson's Disease - HTA -Information Service Review No. 009
Liposuction for the removal of subcutaneous (large) lipomas - HTA-Information Service Rapid Review No. 008
Endovenous laser therapy for varicose veins in the lower extremities
- #195: Pembrolizumab (Keytruda®) for the treatment of adults with endometrial carcinoma
- #194: Pembrolizumab (Keytruda®) with chemoradiotherapy (CRT) for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer
- #193: Mirvetuximab soravtansine (Elahere®) for the treatment of adults with folate receptor-alpha (FR?) positive epithelial ovarian, fallopian tube and primary peritoneal cancer
- #192: Serplulimab (Hetronifly®) with carboplatin and etoposide for the first?line treatment of extensive?stage small cell lung cancer (ES-SCLC)
- #191: Daratumumab (Darzalex®) with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM)
- #190: Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of advanced NSCLC
- #189: Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC)
- #188: Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma
- #187: Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC)
- #186: Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2?negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma
- #185: Toripalimab (Loqtorzi®) with cisplatin and paclitaxel for the first-line treatment of unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC)
- #184: Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC)
- #183: Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL)
- #182: Durvalumab (Imfinzi®) in combination with carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer (EC), followed by maintenance treatment durvalumab (Imfinzi®) as monotherapy in EC that is mismatch repair deficient (dMMR) or in combination with olaparib (Lynparza®) in EC that is mismatch repair proficient (pMMR)
- #181: Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B?cell lymphoma (r/r DLBCL)
- #180: Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)
- #179: Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
- #178 : Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC)
- #177: Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first?line treatment of metastatic non-small-cell lung cancer (NSCLC)
- #176: Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations
- #175: Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion
- #174: Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma
- #173: Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK positive non-small cell lung cancer (NSCLC)
- #172: Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2 negative locally advanced or metastatic breast cancer
- #171: Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC)
- #170: Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC)
- #169: Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours
- #168: Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas
- #167: Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC)
- #166: Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM)
- #165: Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma
- #164: Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
- #163: Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer
- #162: Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies